Table 1.
Clinicopathologic characteristics and PTEN/ERG status for the matched African-American (AA) and European-American (EA) cohort
| Variable | AA (n = 169) | EA (n = 169) | p value |
|---|---|---|---|
| Median age, yr (IQR) | 58 (53–62) | 61 (56–65) | <0.001 |
| Median year of surgery (IQR) | 2001 (1998–2002) | 2001 (1998–2002) | 0.98 |
| Median PSA, ng/ml (IQR) | 8.3 (5.8–13.1) | 6.0 (4.7–8.3) | <0.001 |
| Clinical stage, n (%) | |||
| T1c | 120 (71) | 103 (61) | 0.14 |
| T2a | 32 (19) | 41 (24) | |
| ≥T2b | 17 (10) | 25 (15) | |
| Biopsy grade group, n (%) | |||
| 1 (GS 6) | 91 (54) | 92 (54) | 0.99 |
| 2 (GS 3 + 4) | 41 (24) | 37 (22) | |
| 3 (GS 4 + 3) | 23 (14) | 25 (15) | |
| 4 (GS 8) | 11 (6.5) | 12 (7.1) | |
| 5 (GS 9–10) | 3 (1.8) | 3 (1.8) | |
| RP grade group, n (%) | |||
| 1 (GS 6) | 43 (25) | 43 (25) | 0.99 |
| 2 (GS 3 + 4) | 63 (37) | 63 (37) | |
| 3 (GS 4 + 3) | 31 (18) | 31 (18) | |
| 4 (GS 8) | 23 (14) | 23 (14) | |
| 5 (GS 9–10) | 9 (5) | 9 (5.3) | |
| Pathologic stage, n (%) | |||
| T2N0 | 72 (43) | 76 (45) | 0.7 |
| T3aN0 | 67 (40) | 59 (35) | |
| T3bN0 | 18 (11) | 17 (10) | |
| N1 | 12 (7) | 17 (10) | |
| Tissue microarray, n (%) | |||
| 1 | 110 (65) | 110 (65) | 0.99 |
| 2 | 36 (21) | 36 (21) | |
| 3 | 23 (14) | 23 (14) | |
| Biochemical recurrence (n) | 68 | 67 | |
| 5-yr biochemical recurrence (%) | 44 | 36 | |
| Metastasis (n) | 19 | 20 | |
| 5-yr metastasis (%) | 7 | 8 | |
| PCa death (n) | 10 | 8 | |
| 5-yr PCa death (%) | 1 | 1 | |
| PTEN loss, n (%) | 31 (18) | 57 (34) | 0.001 |
| ERG expression, n (%) | 43 (25) | 87 (52) | <0.001 |
IQR = interquartile range; PSA = prostate-specific antigen; GS = Gleason score; RP = radical prostatectomy; PCa = prostate cancer.